Mohammad Alyamani, MSc, is a 3rd year PhD Student in the Clinical Bioanalytical Chemistry program at Cleveland State University who will graduate in Spring 2017. His PhD research focuses on prostate cancer treatment. The main objective of his research is to study the metabolism of steroids and novel therapeutic agents used in the treatment of castration-resistant prostate cancer (CRPC) and its effect on the androgen receptor, which is important for the growth of prostate cancer cells. He is studying the metabolism by LC-MS/MS methods using CRPC patient serum. He believes that knowing more about steroid metabolism will help solve the puzzle of the therapeutic resistance that develops with current prostate cancer treatments. He is performing his research in Dr. Nima Sharifi’s lab in the Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic.